The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Neuronal Synuclein Disease Endotypes 2024, 2025Developing a Method to Exclude Individuals with Insignificant Alpha-synuclein Aggregates from Trials of Therapies that Target Alpha-synuclein
Study Rationale: Alpha-synuclein is a protein that forms clumps in the brain in Parkinson’s disease (PD). Although alpha-synuclein aggregation is a common cause of dementia, other proteins are also...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Using the Biopark Cohort to Study Neuronal Synuclein Disease Types
Study Rationale: To study the pathogenic processes underlying Parkinson’s disease (PD), we have recruited a cohort of several hundred people, including those with hereditary PD, those that carry PD...
-
Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2024(SUPPLEMENT) Targeting Phosphoinositides for Parkinson’s Disease Therapy
Study Rationale: Phosphoinositides (PIPs) are a group of lipids that build cell membranes and play critical roles in mechanisms that control cell’s growth, movement, propagation and death. Recent...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Alterations in DNA Repair Mechanisms in Parkinson’s Disease Neurons and their Correlation with Clinical Variables
Study Rationale: Preserving the fidelity of genetic information is essential for life. Consequently, all organisms have developed efficient systems for repairing DNA damage. One of the consequences of...
-
Freezing of Gait Program, 2025AID-FOG: Artificial Intelligence-driven Freezing of Gait Detection in the Home
Study Rationale: Freezing of gait (FOG) is a symptom that causes many people with Parkinson’s disease (PD) to suddenly lose their ability to take a step while walking, creating a high risk for falling...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Study Rationale: Forms of alpha-synuclein, the protein that aggregates in Parkinson’s disease (PD), can be detected in cerebrospinal fluid (CSF) by seed amplification assays (SAA). These highly...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.